- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Non-small cell lung cancer (NSCLC)
- Meeting Date: July 2019
- Public Summary Document (PSD) July 2019 PBAC Meeting - (PDF 706KB)
- Public Summary Document (PSD) July 2019 PBAC Meeting - (Word 181KB)
Pembrolizumab – July 2019
Pembrolizumab (NSCLC): Solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda®
Last updated
1 November 2019